ICCB280

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

ICCB280 能够诱导 ATRA 耐药患者原始细胞的分化和凋亡，这强烈表明该化合物的活性可以克服对目前预后不良的 AML 的其他疗法的耐药性。

ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.

ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM.ICCB280 (10 μM; 2-8 d) increases the C/EBPα expression (mRNA and protein) and modulates its target genes in HL-60 cells.ICCB280 (10 μM; 7 d) induces granulocytic differentiation and subsequent apoptosis in HL-60 cells. Cell Viability Assay Cell Line:HL-60 cells Concentration:0.1, 0.5, 1, 5, 10, 50 μM Incubation Time:48 hours Result:Induced cell growth arrest, with an IC50 of 8.6 μM.Western Blot Analysis Cell Line:HL-60 cells Concentration:10 μM Incubation Time:2, 4, 6, 8 days Result:Upregulated the C/EBPα protein on day 4.

——

——

Others

Other Targets

C/EBPα

——

——

2041072-41-5

386.4

C23H18N2O4

>98% (HPLC)

DMSO:85mg/mL (219.98mM)

O=C1N(C2=CC=CC=C2OC)C(/C=C/C3=CC=C(O)C(O)=C3)=NC4=C1C=CC=C4

——

(-20℃)

With Ice Pack

≥ 2 years